Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. In two years, management has hit several key milestones, moving Affimers from being an ‘interesting concept’ to one of ‘real opportunity’ and de-risking the technology as the next platform of biopharmaceutical drugs.
12 Apr 2017
Another important box ticked
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Another important box ticked
Avacta Group PLC (AVCT:LON) | 47.0 -0.5 (-2.1%) | Mkt Cap: 164.7m
- Published:
12 Apr 2017 -
Author:
Martin Hall -
Pages:
12
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. In two years, management has hit several key milestones, moving Affimers from being an ‘interesting concept’ to one of ‘real opportunity’ and de-risking the technology as the next platform of biopharmaceutical drugs.